Highlight
- -LCQ and VAS are two tools to assess cough related quality of life.
- -LCQ and VAS in sarcoidosis are influenced by FeV1 and BMI
- -Serological parameters are not associated with LCQ score
Abstract
Sarcoidosis is a granulomatous disease that mainly manifests within the lungs and
may thereby impair lung function. Beyond and independently from organ impairment,
sarcoidosis may affect quality of life which can be quantified by questionnaires.
The Leicester Cough Questionnaire (LCQ) has been developed to assess cough-related
quality of life. We analysed data from a prospectively collected cohort of sarcoidosis
patients for validation of the German LCQ version. Our analyses demonstrated that
LCQ values add additional information beyond routinely monitored parameters (e.g.
lung function). Only FeV1 and BMI slightly influence LCQ scores, where all other parameters
tested did not correlate with LCQ scores. In summary, LCQ is a valuable tool providing
information on the patient’ quality of life beyond routine follow-up parameters. FeV1
and BMI may represent treatable traits to reduce cough-related disease burden.
Keywords
Abbreviations:
ACE (angiotensin-converting enzyme), BMI (body mass index), DLCO (Diffusion Capacity of the Lungs for Carbon Monoxide), FeV1 (forced expiratory volume in 1 s), FVC (forced vital capacity), LCQ (Leicester Cough Questionnaire), QoL (quality of life), sIL2R (soluble interleukin-2 receptor), TLC (total lung capacity), VAS (Visual analogue scale (for cough))To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Respiratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Use of fluticasone in acute symptomatic pulmonary sarcoidosis.Sarcoidosis Vasc. Diffuse Lung Dis. 2002; 19: 198-204
- Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ).Thorax. 2003; 58: 339-343
- Risk factors for chronic cough among 14,669 individuals from the general population.Chest. 2017; 152: 563-573
- Sarcoidosis.Nature reviews Disease primers. 2019; 5: 45
- Effect of obesity on patient-reported outcomes in sarcoidosis.Int. J. Tubercul. Lung Dis. 2013; 17: 559-564
- The assessment of cough in a sarcoidosis clinic using a validated instrument and a visual analog scale.Lung. 2017; 195: 587-594
- Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features.Chest. 2020; 158: 2007-2014
- R: A Language and Environment for Statistical Computing.R Foundation for Statistical Computing, Vienna, Austria2019
- Psychometric properties of the German version of the leicester cough Questionnaire in sarcoidosis.PloS One. 2018; 13e0205308
- Phenotypes of organ involvement in sarcoidosis.Eur. Respir. J. 2018; 51
Article info
Publication history
Published online: September 07, 2021
Accepted:
August 31,
2021
Received in revised form:
August 29,
2021
Received:
July 24,
2021
Identification
Copyright
© 2021 Elsevier Ltd. All rights reserved.
